Spero therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., oct. 01, 2021 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on september 30, 2021, the compensation committee of spero's board of directors granted non-qualified stock option awards to purchase an aggregate of 12,900 shares of its common stock to three new employees under the spero therapeutics, inc. 2019 inducement equity incentive plan, or the 2019 inducement plan. the stock options were granted as inducements material to the new employees becoming employees of spero in accordance with nasdaq listing rule 5635(c)(4).
SPRO Ratings Summary
SPRO Quant Ranking